Health Technology Assessment: Evaluation of 8 CGRP-Targeted Therapy Drugs for the Treatment of Migraine
Rimegepant, erenumab, fremanezumab, atogepant, galcanezumab, eptinezumab, ubrogepant can be entered into the medication list of medical institutions as strongly recommended drugs.
Authors
- Siyong Huang (ORCID: https://orcid.org/0009-0002-0742-1628)
- Jisheng Chen (ORCID: https://orcid.org/0000-0003-3514-9086)
- Mengyi Li (ORCID: https://orcid.org/0000-0001-6514-1793)
- Jiabao Li (ORCID: https://orcid.org/0000-0002-4518-5198)
- Xiao Hu (ORCID: https://orcid.org/0009-0001-4586-7623)
Institutions
- First Affiliated Hospital of Guangdong Pharmaceutical University (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-02-01
- DOI
- https://doi.org/10.2147/dddt.s499848
- Citations
- 6
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 8.83